Use of quantitative serum HBsAg for optimization of therapy in chronic hepatitis B patients treated with pegylated interferon alfa-2a: A Romanian cohort study

Journal of Gastrointestinal and Liver Diseases

Volumn 22, Issue 1, 2013, Pages 27-32

  Gheorghiţǎ, Valeriu I ^a,b   Cǎruntu, Florin Alexandru ^b,c   Curescu, Manuela ^d,e   Olaru, Ioana ^b   Radu, Monica Nicoleta ^b   Colţan, Gabriel ^b   Streinu Cercel, Adrian ^b,c  

^a Carol Davila Central Military Emergency Hospital   (Romania)

^b Prof Dr Matei Bals National Institute of Infectious Diseases   (Romania)

^c CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^d Clinical Hospital of Infectious Diseases and Pneumology Dr Victor Babes   (Romania)

^e VICTOR BABES UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Chronic hepatitis B; HBsAg; Quantitative HBsAg

Indexed keywords

ALANINE AMINOTRANSFERASE; BIOLOGICAL MARKER; HEPATITIS B SURFACE ANTIGEN; PEGINTERFERON ALPHA2A; VIRUS DNA; ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN;

ADULT; ARTICLE; COHORT ANALYSIS; FEMALE; FOLLOW UP; HEPATITIS B; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PREDICTIVE VALUE; PROSPECTIVE STUDY; REAL TIME POLYMERASE CHAIN REACTION; RELAPSE; ROMANIA; SEROCONVERSION; TREATMENT RESPONSE; VIRUS LOAD; ALGORITHM; BLOOD; DRUG MONITORING; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; ISOLATION AND PURIFICATION; PROCEDURES; TREATMENT OUTCOME; VIROLOGY; YOUNG ADULT;

ADULT; ALGORITHMS; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; COHORT STUDIES; DNA, VIRAL; DRUG MONITORING; FEMALE; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 84875432848     PISSN: 18418724     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. European Association for the Study of the Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012;57:167-185.
2. Rijckborst V, Hansen BE, Ferenci P, et al. Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a. J Hepatol 2012;56:1006-1011.
3. Liaw YF, Kao JH, Piratvisuth T, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int 2012;6:531-561.
4. Chan HL, Thompson A, Martinot-Peignoux M, et al. Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report. J Hepatol 2011;55:1121-1131.
5. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009;50:661-662.
6. Caruntu FA. Prevalence of HBeAg and HBV Genotypes in Romania. Gastroentrology 2008; 134(supp 1): A-807 (Abstract).
7. Sonneveld MJ, Zoutendijk R, Janssen HL. Hepatitis B surface antigen monitoring and management of chronic hepatitis B. J Viral Hepat 2011; 18:449-457.
8. Liaw YF. Clinical utility of hepatitis B surface antigen quantitation in patients with chronic hepatitis B: a review. Hepatology 2011; 53:2121-2129.
9. Brunetto MR. A new role for an old marker, HBsAg. J Hepatol 2010; 52:475-477.
10. Chan HL, Wong VW, Wong GL, Tse CH, Chan HY, Sung JJ. A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B. Hepatology 2010; 52:1232-1241.
11. Jaroszewicz J, Calle Serrano B, Wursthorn K, et al. Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: A European perspective. J Hepatol 2010; 52:514-522.
12. Sonneveld MJ, Rijckborst V, Senturk H, et al. HBsAg decline during peginterferon alfa-2b therapy for HBeAg-positive chronic hepatitis B depends on HBV genotype: relation to sustained response. Hepatology 2010; 52: 441 (Abstract).
13. Wursthorn K, Jung M, Riva A, et al. Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients. Hepatology 2010; 52:1611-1620.
14. Brunetto MR, Oliveri F, Colombatto P, et al. Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers. Gastroenterology 2010; 139:483-490.
15. Moucari R, Mackiewicz V, Lada O, et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2009; 49:1151-1157.
16. Chan HL, Wong VW, Chim AM, Chan HY, Wong GL, Sung JJ. Serum HBsAg quantification to predict response to peginterferon therapy of e antigen positive chronic hepatitis B. Aliment Pharmacol Ther 2010; 32:1323-1331.
17. Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351:1206-1217.
18. Rijckborst V, Ter Borg MJ, Cakaloglu Y, et al. A randomized trial of peginterferon alpha-2a with or without ribavirin for HBeAg-negative chronic hepatitis B. Am J Gastroenterol 2010; 105:1762-1769.